Sponsored message
Audience-funded nonprofit news
radio tower icon laist logo
Next Up:
0:00
0:00
Subscribe
  • Listen Now Playing Listen
Health

FDA Authorizes First Revamp Of COVID Vaccines To Target Omicron

Vials of COVID-19 vaccine booster are on a circular surface
Vials of the newly reformulated COVID-19 vaccine booster are being readied by Pfizer for distribution now that the Food and Drug Administration has authorized the shots for people 12 and older.
(
Pfizer Inc.
)

Truth matters. Community matters. Your support makes both possible. LAist is one of the few places where news remains independent and free from political and corporate influence. Stand up for truth and for LAist. Make your tax-deductible donation now.

The Food and Drug Administation authorized reformulated versions of the Moderna and Pfizer-BioNTech vaccines that aim to protect against the omicron variant.

The new shots target both the original strain of the coronavirus and the omicron BA.4/BA.5 subvariants that most people are catching now. This double-barreled vaccine is called a bivalent vaccine.

"The FDA has been planning for the possibility that the composition of the COVID-19 vaccines would need to be modified to address circulating variants. ... We have worked closely with the vaccine manufacturers to ensure the development of these updated boosters was done safely and efficiently," said Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, in an agency statement. "The FDA has extensive experience with strain changes for annual influenza vaccines. We are confident in the evidence supporting these authorizations."

The Moderna COVID-19 vaccine is authorized for use as a single booster dose in people 18 and older. The Pfizer-BioNTech booster is authorized for people 12 years and up.

The federal government plans to make the boosters available starting next week. In advance of the FDA's decision, Dr. Ashish Jha, the White House COVID-19 Response Coordinator told NPR that the new boosters represented "a really important moment in this pandemic."

Public health officials hope they will help contain a possible fall and winter surge.

Sponsored message

But there is also skepticism about how big a difference the boosters can make. "It could be problematic if the public thinks that the new bivalent boosters are a super-strong shield against infection, and hence increased their behavioral risk and exposed themselves to more virus," John Moore, an immunologist at Weill Cornell Medicine in New York, told NPR.

Copyright 2024 NPR. To see more, visit npr.org.

You come to LAist because you want independent reporting and trustworthy local information. Our newsroom doesn’t answer to shareholders looking to turn a profit. Instead, we answer to you and our connected community. We are free to tell the full truth, to hold power to account without fear or favor, and to follow facts wherever they lead. Our only loyalty is to our audiences and our mission: to inform, engage, and strengthen our community.

Right now, LAist has lost $1.7M in annual funding due to Congress clawing back money already approved. The support we receive from readers like you will determine how fully our newsroom can continue informing, serving, and strengthening Southern California.

If this story helped you today, please become a monthly member today to help sustain this mission. It just takes 1 minute to donate below.

Your tax-deductible donation keeps LAist independent and accessible to everyone.
Senior Vice President News, Editor in Chief

Make your tax-deductible donation today

A row of graphics payment types: Visa, MasterCard, Apple Pay and PayPal, and  below a lock with Secure Payment text to the right